Docetaxel Injection
Product Images NDC 62332-678

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 62332-678). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Docetaxel-160mg-carton (Docetaxel 160mg Carton)

Docetaxel Injection, USP 160 mg/16 mL (10 mg/mL) vial label for intravenous use by Alembic Pharmaceuticals Inc. Multiple-dose vial, NDC 62332-678-16. Label emphasizes ready to add to infusion solution, cytotoxic agent caution, and storage instructions. Includes dosage and handling details with manufacturing information and barcode on flaps.*

FDA Label Image

Docetaxel-160mg-vial (Docetaxel 160mg Vial)

Label for Docetaxel Injection, USP 160 mg/16 mL (10 mg/mL) multiple-dose vial by Alembic Pharmaceuticals Inc. Contains 10 mg/mL Docetaxel, polysorbate, citric acid, dehydrated alcohol, and polyethylene glycol. Intended for intravenous use only. Storage instructions: 20° to 25°C, protect from light.*

FDA Label Image

Docetaxel-20mg-carton (Docetaxel 20mg Carton)

Packaging label for Docetaxel Injection, USP 20 mg/2 mL (10 mg/mL) single-dose vial for intravenous use. The label includes preparation instructions, caution that the drug is a cytotoxic agent, storage information, and manufacturer details for Alembic Pharmaceuticals Inc. The label design uses Pantone colors and includes barcodes and NDC 62332-678-02.*

FDA Label Image

Docetaxel-20mg-vial (Docetaxel 20mg Vial)

Label for Docetaxel Injection, USP, 20 mg/2 mL (10 mg/mL) intravenous injection by Alembic Pharmaceuticals Inc. Indicates single-dose vial, cautions cytotoxicity, storage temperature 20° to 25°C, and instructs to discard unused portion. Includes barcode, lot number, and expiration date area.*

FDA Label Image

Docetaxel-80mg-carton (Docetaxel 80mg Carton)

Packaging label for Docetaxel Injection, USP 80 mg per 8 mL (10 mg/mL) intravenous injection by Alembic Pharmaceuticals Inc. The label states it is a multiple-dose vial, ready to add to infusion solution, and includes safety warnings about cytotoxicity. The label shows NDC 62332-678-08 and storage instructions.*

FDA Label Image

Docetaxel-80mg-vial (Docetaxel 80mg Vial)

Label for Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) sterile intravenous injection in an 8 mL multiple-dose vial. The label includes dosage strength, usage instructions noting it is ready to add to infusion solution, and a caution indicating it is a cytotoxic agent. Manufactured by Alembic Pharmaceuticals Inc.*

FDA Label Image

Docetaxel-figure-1 (Docetaxel Figure 1)

A Kaplan-Meier curve titled "TAX316 Disease Free Survival K-M Curve" showing disease-free survival probability (%) over time in months. The graph compares two treatment groups, TAC and FAC, with DFS probability decreasing over approximately 66 months.*

FDA Label Image

Docetaxel-figure-10 (Docetaxel Figure 10)

A Kaplan-Meier curve titled 'Figure 10 - TAX324 Overall Survival K-M Curve' showing survival probability (%) over survival time (months). It compares two groups, TPF (n=255) and PF (n=246), with survival probabilities plotted over 72 months. Below the graph, tables show the number of patients at risk at various time points for each group.*

FDA Label Image

Docetaxel-figure-2 (Docetaxel Figure 2)

A Kaplan-Meier survival curve graph titled 'Figure 2 - TAX316 Overall Survival K-M Curve' showing survival probability (%) on the y-axis and survival time in months on the x-axis. The graph compares two groups labeled TAC and FAC, illustrating overall survival trends over a time period up to 72 months.*

FDA Label Image

Docetaxel-figure-3 (Docetaxel Figure 3)

A Kaplan-Meier survival curve chart comparing overall survival between Docetaxel 75 mg/m² and Best Supportive Care (BSC) groups. The X-axis shows survival time in months, and the Y-axis shows cumulative probability. Docetaxel group displays a higher survival probability over time compared to BSC, with a reported log-rank p value of 0.010 indicating statistical significance.*

FDA Label Image

Docetaxel-figure-4 (Docetaxel Figure 4)

A Kaplan-Meier survival curve graph comparing overall survival probabilities over time (in months) for Docetaxel 75 mg/m² versus Vinorelbine or Ifosfamide control treatments. The graph displays cumulative survival probability on the vertical axis and survival time in months on the horizontal axis, including a log-rank p-value of 0.13.*

FDA Label Image

Docetaxel-figure-5 (Docetaxel Figure 5)

A Kaplan-Meier survival curve chart labeled Figure 5 - TAX327 Survival K-M Curves. The chart compares survival probability over time in months, with two curves labeled T75 q3w and M q3w, showing survival probabilities declining from 1.0 to near 0 over a 30-month period.*

FDA Label Image

Docetaxel-figure-6 (Docetaxel Figure 6)

A Kaplan-Meier curve chart showing time to progression in months for a gastric cancer study (TAX325). The y-axis represents probability percentage, and two treatment groups, TCF and CF, are compared over a 24-month period.*

FDA Label Image

Docetaxel-figure-7 (Docetaxel Figure 7)

A survival Kaplan-Meier curve from a gastric cancer study (TAX325) showing survival probability (%) over time (months). The graph compares two groups, TCF and CF, with survival probabilities decreasing over 36 months.*

FDA Label Image

Docetaxel-figure-8 (Docetaxel Figure 8)

A Kaplan-Meier curve titled 'Figure 8 - TAX323 Progression-Free Survival K-M Curve,' depicting progression-free survival probability (%) over time in months for two groups labeled TPF and PF. The chart shows a decreasing survival probability over 42 months, with TPF having higher survival probabilities compared to PF throughout the time period.*

FDA Label Image

Docetaxel-figure-9 (Docetaxel Figure 9)

A Kaplan-Meier survival curve titled 'Figure 9 - TAX323 Overall Survival K-M Curve' showing survival probability percentages over time in months. The graph compares two groups, TPF and PF, with survival time on the x-axis and survival probability on the y-axis, illustrating overall survival trends up to 72 months.*

FDA Label Image

Docetaxel-structure (Docetaxel Structure)

Chemical structure of Docetaxel, the active ingredient in the injection product by Alembic Pharmaceuticals Inc. The structure shows the detailed molecular arrangement including rings, hydroxyl groups, and ester linkages characteristic of this chemotherapeutic agent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.